Compare · MDGL vs NVO
MDGL vs NVO
Side-by-side comparison of Madrigal Pharmaceuticals Inc. (MDGL) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDGL and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 16.3x MDGL ($10.62B).
- Over the past year, MDGL is up 2.4% and NVO is down 28.6% - MDGL leads by 30.9 points.
- Both names hit the wire about 4 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- Madrigal Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $449.34-2.24%
- $38.82-1.05%
- Market cap
- $10.62B
- $173.66B
- 1M return
- -15.95%
- -10.14%
- 1Y return
- +2.36%
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2007
- News (4w)
- 4
- 4
- Recent ratings
- 25
- 25
Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is MGL-3196, a liver-directed selective thyroid hormone receptor-Ã agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MDGL
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
- Goldman resumed coverage on Madrigal Pharmaceuticals with a new price target
- Citigroup initiated coverage on Madrigal Pharmaceuticals with a new price target
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- President and CEO Sibold William John sold $6,239,198 worth of shares (11,583 units at $538.65) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 197,746 units (SEC Form 4) (for tax liability)
- Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
- General Counsel Kelley Shannon T sold $341,940 worth of shares (664 units at $514.97), decreasing direct ownership by 5% to 11,474 units (SEC Form 4) to cover taxes
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Director Reed John C was granted 647 shares (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank